Ilya Tsimafeyeu1, Mark Temper2. 1. Institute of Oncology, Hadassah Moscow, Moscow, Russian Federation. 2. Hadassah Medical Center, Jerusalem, Israel.
Abstract
BACKGROUND: Cholangiocarcinoma has been traditionally considered a tumor with poor prognosis. Until now, surgical treatment has been the only more or less effective approach. SUMMARY: Over 10 years, chemotherapy with a combination of gemcitabine and cisplatin remains the standard first-line therapy for patients with locally advanced or metastatic cholangiocarcinoma, which leads to a median overall survival of 11.7 months. Several inhibitors of HER (ERBB), HGF/c-MET, Hedgehog, KRAS-BRAF-MEK-ERK, and PI3K/AKT/mTOR signaling pathways did not show their superiority to standard chemotherapy. The rise of hope is associated with the emergence of novel fibroblast growth factor receptors and isocitrate dehydrogenase inhibitors as well as immune checkpoint inhibitors.
BACKGROUND: Cholangiocarcinoma has been traditionally considered a tumor with poor prognosis. Until now, surgical treatment has been the only more or less effective approach. SUMMARY: Over 10 years, chemotherapy with a combination of gemcitabine and cisplatin remains the standard first-line therapy for patients with locally advanced or metastatic cholangiocarcinoma, which leads to a median overall survival of 11.7 months. Several inhibitors of HER (ERBB), HGF/c-MET, Hedgehog, KRAS-BRAF-MEK-ERK, and PI3K/AKT/mTOR signaling pathways did not show their superiority to standard chemotherapy. The rise of hope is associated with the emergence of novel fibroblast growth factor receptors and isocitrate dehydrogenase inhibitors as well as immune checkpoint inhibitors.
Authors: Richard D Kim; Vincent Chung; Olatunji B Alese; Bassell F El-Rayes; Daneng Li; Taymeyah E Al-Toubah; Michael J Schell; Jun-Min Zhou; Amit Mahipal; Baek Hui Kim; Dae Won Kim Journal: JAMA Oncol Date: 2020-06-01 Impact factor: 31.777
Authors: Maeve A Lowery; Laura W Goff; Bridget P Keenan; Emmet Jordan; Rui Wang; Andrea G Bocobo; Joanne F Chou; Eileen M O'Reilly; James J Harding; Nancy Kemeny; Marianela Capanu; Ann C Griffin; Joseph McGuire; Alan P Venook; Ghassan K Abou-Alfa; Robin K Kelley Journal: Cancer Date: 2019-08-27 Impact factor: 6.860
Authors: Ghassan K Abou-Alfa; Teresa Macarulla; Milind M Javle; Robin K Kelley; Sam J Lubner; Jorge Adeva; James M Cleary; Daniel V Catenacci; Mitesh J Borad; John Bridgewater; William P Harris; Adrian G Murphy; Do-Youn Oh; Jonathan Whisenant; Maeve A Lowery; Lipika Goyal; Rachna T Shroff; Anthony B El-Khoueiry; Bin Fan; Bin Wu; Christina X Chamberlain; Liewen Jiang; Camelia Gliser; Shuchi S Pandya; Juan W Valle; Andrew X Zhu Journal: Lancet Oncol Date: 2020-05-13 Impact factor: 41.316
Authors: Shahid A Khan; Brian R Davidson; Robert D Goldin; Nigel Heaton; John Karani; Stephen P Pereira; William M C Rosenberg; Paul Tait; Simon D Taylor-Robinson; Andrew V Thillainayagam; Howard C Thomas; Harpreet Wasan Journal: Gut Date: 2012-08-15 Impact factor: 23.059
Authors: Alessandro Rizzo; Angela Dalia Ricci; Antonio Cusmai; Silvana Acquafredda; Giuseppe De Palma; Giovanni Brandi; Gennaro Palmiotti Journal: Curr Oncol Date: 2022-01-27 Impact factor: 3.677